Bio-Techne (TECH) Expected to Announce Earnings on Wednesday

Bio-Techne (NASDAQ:TECH - Get Free Report) is expected to be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.52 per share and revenue of $317.92 million for the quarter.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Up 1.7 %

Shares of NASDAQ:TECH traded up $0.86 on Friday, reaching $50.49. The company had a trading volume of 1,525,113 shares, compared to its average volume of 1,208,525. The stock has a market capitalization of $7.98 billion, a P/E ratio of 51.00, a P/E/G ratio of 2.88 and a beta of 1.46. The stock has a 50-day moving average price of $55.92 and a 200 day moving average price of $66.95. Bio-Techne has a twelve month low of $46.01 and a twelve month high of $85.57. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were issued a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a yield of 0.63%. Bio-Techne's dividend payout ratio (DPR) is currently 32.32%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TECH shares. Royal Bank of Canada boosted their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 6th. Evercore ISI began coverage on Bio-Techne in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $75.00 price target on the stock. Robert W. Baird lowered Bio-Techne from an "outperform" rating to a "neutral" rating and dropped their price objective for the stock from $88.00 to $68.00 in a research note on Wednesday, February 19th. KeyCorp restated a "sector weight" rating on shares of Bio-Techne in a research note on Wednesday, April 9th. Finally, Scotiabank lifted their price target on Bio-Techne from $88.00 to $90.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 6th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $81.14.

Insider Transactions at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the transaction, the director now owns 1,976 shares of the company's stock, valued at $130,336.96. This represents a 48.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.90% of the stock is owned by insiders.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.